DURHAM, N.C., Aug. 28, 2024 /PRNewswire/ — EydisBio, an early-stage pharmaceutical company leveraging a novel approach to treating various autoimmune and inflammatory diseases, is thrilled to announce that it has been awarded a $2.6 million Phase 2 Small Business Innovation Research…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.